We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+27.09%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$11.7B
AUM Growth
+$1.66B
Cap. Flow
-$50.3M
Cap. Flow %
-0.43%
Top 10 Hldgs %
47.72%
Holding
97
New
9
Increased
26
Reduced
8
Closed
13

Top Buys

Rank Stock Value
1
KLRA
Kailera Therapeutics
KLRA
+$237M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$103M
3
CGON icon
CG Oncology
CGON
+$100M
4
ORKA
Oruka Therapeutics
ORKA
+$72M
5
GPCR icon
Structure Therapeutics
GPCR
+$71.1M

Top Sells

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$234M
2
APLS
Apellis Pharmaceuticals
APLS
+$148M
3
COGT icon
Cogent Biosciences
COGT
+$110M
4
ISRG icon
Intuitive Surgical
ISRG
+$101M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$81.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
2 Financials 0.07%
3 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
51
Solid Biosciences
SLDB
$1.05B
$38.9M 0.33%
+3,892,926
New +$29.5M
SVRA icon
52
Savara
SVRA
$1.08B
$36.7M 0.31%
5,952,380
– –
AQST icon
53
Aquestive Therapeutics
AQST
$630M
$30.9M 0.26%
7,426,471
– –
KYMR icon
54
Kymera Therapeutics
KYMR
$9.82B
$27.5M 0.24%
240,000
– –
VSTM icon
55
Verastem
VSTM
$654M
$25.3M 0.22%
6,635,793
+59,487
+0.9% +$288K
DNTH icon
56
Dianthus Therapeutics
DNTH
$5.92B
$24.2M 0.21%
248,063
– –
BBNX
57
Beta Bionics
BBNX
$887M
$23.5M 0.2%
1,500,000
-500,000
-25% -$5.95M
IPSC icon
58
Century Therapeutics
IPSC
$366M
$21.3M 0.18%
8,695,652
– –
EVMN
59
Evommune Inc
EVMN
$480M
$20M 0.17%
1,502,235
– –
BEAM icon
60
Beam Therapeutics
BEAM
$3.03B
$19.6M 0.17%
570,394
– –
DFTX
61
Definium Therapeutics
DFTX
$5.51B
$18.8M 0.16%
400,000
+100,000
+33% +$2.47M
IDYA icon
62
IDEAYA Biosciences
IDYA
$3.87B
$13.8M 0.12%
+370,370
New +$11.3M
ATAI icon
63
AtaiBeckley Inc
ATAI
$2.7B
$10.5M 0.09%
2,000,000
– –
MIST icon
64
Milestone Pharmaceuticals
MIST
$144M
$10.5M 0.09%
7,833,336
+1,502,335
+24% +$2.4M
OCGN icon
65
Ocugen
OCGN
$448M
$10.2M 0.09%
6,666,666
– –
TENX icon
66
Tenax Therapeutics
TENX
$79.7M
$10.1M 0.09%
696,570
+326,324
+88% +$4.17M
HTFL
67
Heartflow Inc
HTFL
$4.15B
$8.66M 0.07%
295,000
-200,000
-40% -$6.01M
PCSC
68
DELISTED
Perceptive Capital Solutions
PCSC
$8.08M 0.07%
742,500
– –
WVE icon
69
Wave Life Sciences
WVE
$993M
$7.84M 0.07%
1,350,000
– –
LRMR icon
70
Larimar Therapeutics
LRMR
$417M
$7.83M 0.07%
2,565,999
+1,065,999
+71% +$4.23M
LMRI
71
Lumexa Imaging Holdings
LMRI
$1.11B
$7.33M 0.06%
650,000
– –
ALLO icon
72
Allogene Therapeutics
ALLO
$698M
$6.76M 0.06%
+3,250,000
New +$7.14M
CBIO
73
Crescent Biopharma
CBIO
$659M
$6.71M 0.06%
372,856
– –
FDMT icon
74
4D Molecular Therapeutics
FDMT
$810M
$6.33M 0.05%
475,737
– –
MAZE
75
Maze Therapeutics
MAZE
$1.52B
$6.33M 0.05%
+212,000
New +$5.56M
1 2
3
4

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q2 2026 Portfolio in Review

As of Q2 2026, RTW Investments held 97 positions worth $11.7B, up 17% from $10B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

RTW Investments's Q2 2026 filing shows 9 new, 26 increased, 8 reduced and 13 closed positions. Its largest new stake was Kailera Therapeutics: 10,776,820 shares worth $237M. The largest sale was Apogee Therapeutics, an estimated $234M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials and Miscellaneous.

  • RTW Investments's largest Q2 2026 buy was Kailera Therapeutics: 10,776,820 shares worth $237M.
  • RTW Investments added most to Ultragenyx Pharmaceutical in Q2 2026, an estimated $103M increase.
  • RTW Investments's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $110M.
  • RTW Investments fully exited Apogee Therapeutics in Q2 2026, selling an estimated $234M.
  • RTW Investments's ten largest holdings make up 48% of its $11.7B portfolio in Q2 2026.
  • RTW Investments opened 9 new positions and closed 13 in Q2 2026.
  • RTW Investments's portfolio value rose 17% quarter-over-quarter to $11.7B.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.